Pfizer wins $10 billion bidding war for obesity drug developer
1. Pfizer secures $10 billion acquisition of obesity drug developer Metsera. 2. Metsera's potential treatments may tap into a $150 billion market. 3. Novo Nordisk exits bidding due to antitrust concerns and will refocus on its own pipeline. 4. Analysts highlight Pfizer's optimistic revenue expectations for Metsera's drugs. 5. Fierce competition signifies the critical role of obesity drugs in Pfizer's future.